Business Wire

New ISACA Certification Helps Students and Career Changers Build IT Knowledge and Hands-On Skills to Thrive in IT Jobs

Share

Those seeking a strong foundation in IT knowledge and hands-on experience to set themselves apart as they seek technology jobs can now earn the new Information Technology Certified Associate (ITCA) certification from global IT professional association and learning organization ISACA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005796/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

As the need for skilled technology professionals continues to grow, the IT field presents numerous promising career paths for young professionals, recent graduates and career-changers. ISACA’s new Information Technology Certified Associate (ITCA) credential – which includes certificates in Computing Fundamentals, Networks and Infrastructure Fundamentals, Cybersecurity Fundamentals, Data Science Fundamentals and Software Development Fundamentals – prepares aspiring professionals for entry into an array of IT fields. (Graphic: Business Wire)

A dynamic addition to ISACA’s globally recognized credentials, ITCA offers students, recent graduates, those new to the IT profession or professionals seeking a career change with a flexible, hybrid format comprised of traditional knowledge-based learning and performance-based learning through live labs in a virtual environment. The certification can be achieved at one’s own pace by completing all the following modular certificates that focus on different domain areas in IT:

  • Computing Fundamentals
  • Networks and Infrastructure Fundamentals
  • Cybersecurity Fundamentals
  • Software Development Fundamentals
  • Data Science Fundamentals

“A key part of ISACA’s commitment to providing tools for lifelong learning is supporting professionals at every stage of their career journey, including in that critical period at the very beginning—whether they are new graduates or professionals seeking to make a career change to IT,” says David Samuelson, ISACA CEO. “We are proud to be able to serve this new generation of IT professionals and thought leaders, including those transitioning their careers due to the pandemic, by helping them differentiate and elevate themselves as they enter the job market and start their careers.”

With ITCA, young professionals, students or recent graduates with degrees in IT or computer science, and those seeking a job change can prepare themselves for in-demand jobs like computer systems administrator, technical support specialist, database administrator, systems engineer, applications developer, front-end web developer, and quality assurance analyst. The certification can also serve more experienced audit, security or governance professionals looking to enhance their understanding of foundational IT concepts.

“Working within the IT industry presents so many amazing opportunities for recent graduates, young professionals and career-changers,” says Daisy Jardine-Viner, recruitment specialist, NDK Infosec. “It’s a constantly evolving and in-demand hiring environment that offers the chance to work at the forefront of technology.”

The ITCA program offers study guides, self-paced training courses, performance-based labs, and exams for each certificate, available at discounted rates to ISACA members. Once all five exams are completed, the candidate can apply to become ITCA certified.

For more information about ITCA, visit www.isaca.org/credentialing/itca. Learn more about ISACA’s other credentials at www.isaca.org/credentialing.

About ISACA

For more than 50 years, ISACA® (www.isaca.org) has been equipping individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enables enterprises to train and build quality teams. ISACA leverages the expertise of its more than 150,000 members to drive innovation through technology. It has a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Emily Van Camp, evcamp@isaca.org, +1.847.385.7223
Kristen Kessinger, communications@isaca.org, +1.847.660.5512

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye